智通财经网·2025-05-12 02:22Group 1 - Eli Lilly's weight loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, showing superior results in five weight loss metrics [1] - Zepbound helped nearly 25% of participants lose over 15% of their body weight, while the average waist circumference reduction was 18.4 cm for Zepbound compared to 13 cm for Wegovy [1] - Zepbound's mechanism mimics two gut hormones for weight loss, whereas Wegovy operates through a more singular mechanism [1] Group 2 - The data from the trial supports Eli Lilly's efforts to gain broader insurance coverage for Zepbound and highlights its competitive advantages in the weight loss drug market [2] - The weight loss drug market is projected to exceed $150 billion in annual sales over the next decade, intensifying competition between Eli Lilly and Novo Nordisk [2] - CVS Health recently removed Zepbound from its reimbursement list in favor of Wegovy, adding complexity to the competitive landscape in the weight loss drug market [2]